Redefining what's possible in genetic analysis
Introducing our work
Here at Depixus we are developing a platform for analysing the genomics of biological systems at new levels of resolution.
Our MAGNATM technology goes beyond decoding the static genetic code to reveal the dynamics of the genome that control health and disease.
We analyse single native molecules of DNA, RNA and protein to bring new insights across important emerging areas of biology. 
Senior Team
Dr. Gordon Hamilton MA MBBS MBA
Gordon is the CEO of Depixus. He brings experience of translational research and bioscience commercialization having worked as Medical Director for ChemoCentryx, a successful Silicon Valley biopharmaceutical company. He has previously also founded and built-up The Electives Network Ltd, an international medical education company. He has a First Class Master’s degree in Physiological Sciences from the University of Oxford, a medical degree from Imperial College School of Medicine, and an MBA from INSEAD.
Dr. Chas André BA PhD
Chas has over 17 years of experience successfully bringing life science tools to market with companies such as Applied Biosystems, MJ Research; BioRad, and Thermo Fisher Scientific. He graduated from The University of Chicago with a bachelor’s degree in biology, and earned a Ph.D. in Genetics from Stanford University. He has overseen the launch of dozens of products in the PCR, qPCR and DNA sequencing sectors, including instruments, consumables, and software, with a particular focus on applications and system integration.
Jimmy Ouellet PhD
Jimmy leads Depixus’ molecular biology activities. He has more than 15 years of research experience in areas spanning molecular biology, cell biology, oncology, and live microscopy. Jimmy has a PhD in biology from McGill University (Montréal, Canada) and did his post-doctoral training at the Swiss Federal Institute of Technology (ETH, Zürich Switzerland). Before joining Depixus in early 2015, he worked in the “Laboratoire de Physique Statistique” (LPS) of École Normale Supérieure in Paris. Here he was a member of the research group of Vincent Croquette, David Bensimon, and Jean-Francois Allemand, Depixus’ academic founders.
Pol d’Avezac PhD
Pol has been leading the data science effort for Depixus since joining the company in April 2016. He holds an engineering degree and a Ph.D. in particle physics from the Ecole Polytechnique. Since then, he has worked as a data scientist and R&D computer engineer, acquiring experience within both startups and multinational companies, in fields ranging from heavy process industries to medical instrumentation and geophysics.
Thibault Vieille PhD
Carl Glasse
Board Members
John Berriman
John Berriman is the Chairman of ReNeuron Group plc (listed on AIM) and Autifony Therapeutics Ltd; and past Chairman of Heptares Therapeutics Ltd (sold to Sosei in February 2015) and Algeta ASA (listed on the Oslo stock exchange and sold to Bayer AG in March 2014). He is also a non-executive director of Autolus Ltd. Until its sale to Amgen in the spring of 2012 he was a director of Micromet Inc. (listed on NASDAQ). Previously he was a director of Cytos AG (listed on the SIX Swiss exchange) and Abingworth Management, an international healthcare venture capital firm, where he was involved in founding, financing and serving as a director of several biotechnology companies in Europe and the USA – many of which obtained listings on public stock exchanges. Prior to that, he spent 14 years with Celltech Group plc and was a member of its Board when it listed on the London Stock Exchange in 1994. He has a degree in Chemical Engineering from the University of Cambridge and a Masters degree from the London Business School. In addition to the positions mentioned above, he was a founder and the first chairman of Solexa Ltd (now owned by Illumina Inc) the company which developed the DNA sequencing technology which is the dominant method of gene sequencing today.
Ronald Lindsay
Dr Ronald Lindsay is currently the Chief Executive Officer of Zebra Biologics, Inc., a company developing a disruptive new antibody generating platform. He previously served as Executive Vice President of Strategic Planning at Sequenom Inc, a company that pioneered the use of next generation sequencing for non-invasive prenatal diagnostics. Prior to Sequenom, Dr Lindsay held a variety of senior biopharmaceutical positions, directing discovery and preclinical research efforts in cancer, neuroscience, and genomics. He has served as Vice President, Research and Development, and Chief Science Officer of diaDexus, Inc; has been a Senior Advisor at the German venture capital fund TVM Capital GmbH; was a Member of the Scientific Advisory Board of Merck Serono S.A, has held various senior management roles with Millennium Pharmaceuticals, Inc; and was a co-founder of Regeneron Pharmaceuticals, Inc., today a pharmaceutical company with a market capitalisation of ~$40bn. He began his industry career as Head of Cell Biology at the Sandoz Institute for Medical Research, University College in London. He has authored over 150 scientific articles and was recognized by the Institute for Scientific Information as one of the most highly cited neuroscientists of the 1990's. He is also the holder of multiple patents. He has Ph.D. in Biochemistry from the University of Calgary and a B.Sc. (Honours) in Chemistry from the University of Glasgow.
Jonathan Tobin
Jonathan specialises in biotechnology investments. He currently sits on the boards of several Arix portfolio companies: Artios Pharma, Atox Bio, STipe Therapeutics, Quench Bio, VelosBio and Depixus. He is also responsible for managing the other members of the investment team. Prior to joining Arix Bioscience, Jonathan spent five years at Touchstone Innovations (formerly Imperial Innovations), where he was a Principal in the Healthcare Ventures team. He was involved with the formation of a number of early stage UK biotech companies. Previously, Jonathan worked at LifeArc, sourcing and evaluating new small molecule and antibody drug discovery projects. He has a first-class degree in biology from the University of Oxford, a PhD in Molecular Medicine from UCL, carried out postdoctoral research at the Cancer Research UK London Research Institute (now Crick Institute), and published research in journals including PNAS, New England Journal of Medicine, and Nature Genetics. Jonathan has an MBA with Distinction from Imperial College Business School, is a Trustee of the Autism Centre of Excellence, and a member of the Investment Advisory Committee for the KHAN-I fund, an early stage biotech fund based in Germany focused on translating academic discoveries into new therapeutics.
Investors
Early-stage investors
Depixus has strong backing from experienced early-stage investors, several of whom are veterans of the sequencing industry.
Other
We are also supported financially via a variety of grants and awards.
Venture Capital
Depixus is also backed by Arix Bioscience Limited, a global venture capital company focussed on investing in and building breakthrough biotechnology companies around cutting-edge advances in the life sciences. 